1
|
Bhattacharya S. Emergencies in Pulmonary Hypertension. Cardiol Clin 2024; 42:273-278. [PMID: 38631794 DOI: 10.1016/j.ccl.2024.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/19/2024]
Abstract
Pulmonary hypertension is a challenging disease entity with various underlying etiologies. The management of patients with pulmonary arterial hypertension (WHO Group 1) remains challenging especially in the critical care setting. With risk of high morbidity and mortality, these patients require a multidisciplinary team approach at a speciality care facility for pulmonary hypertension for comprehensive evaluation and rapid initiation of treatment. For acute decompensated right heart failure, management should concentrate on optimizing preload and after load with use of pulmonary vasodilator therapy. A careful evaluation of specialized situations is required for appropriate treatment response.
Collapse
Affiliation(s)
- Sanjeeb Bhattacharya
- Section of Heart Failure and Cardiac Transplantation, Cleveland Clinic, 9500 Euclid Avenue, Suite J3-4, Cleveland, OH 44195, USA.
| |
Collapse
|
2
|
Torbic H, Tonelli AR. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting. J Cardiovasc Pharmacol Ther 2024; 29:10742484231225310. [PMID: 38361351 DOI: 10.1177/10742484231225310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2024]
Abstract
Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progressive disease that may lead to death as a result of right ventricular (RV) failure. During acute on chronic RV failure it is critical to decrease the pulmonary vascular resistance with the goal of improving RV function and prognosis; therefore, aggressive PAH-treatment based on disease risk stratification is essential. Pulmonary arterial hypertension treatment for acute on chronic RV failure can be impacted by end-organ damage, hemodynamic instability, drug interactions, and PAH medications dosage and delivery. Sotatercept, a first in class activin signaling inhibitor that works on the bone morphogenetic protein/activin pathway is on track for Food and Drug Administration approval for the treatment of PAH based on results of recent trials in where the medication led to clinical and hemodynamic improvements, even when added to traditional PAH-specific therapies. The purpose of this review is to highlight important considerations when starting or continuing sotatercept in patients admitted to the hospital with PAH.
Collapse
Affiliation(s)
- Heather Torbic
- Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA
| | - Adriano R Tonelli
- Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
3
|
Fronrath MJ, Hencken L, Martz CR, Kelly B, Smith ZR. Fluid resuscitation and relation to respiratory support escalation in patients with and without pulmonary hypertension with sepsis. Pharmacotherapy 2024; 44:61-68. [PMID: 37728179 DOI: 10.1002/phar.2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 07/14/2023] [Accepted: 08/28/2023] [Indexed: 09/21/2023]
Abstract
STUDY OBJECTIVE To compare guideline-based fluid resuscitation and need for respiratory support escalation in septic patients with pulmonary hypertension (PH) to those without PH. DESIGN Single-center, retrospective cohort study. SETTING Tertiary care academic medical center in Detroit, Michigan. PATIENTS Adult patients with or without PH hospitalized and diagnosed with sepsis from November 1, 2013 through December 31, 2019. Patients with sepsis were assigned to one of two groups based on a previous PH diagnosis or no PH diagnosis. INTERVENTION None. MEASUREMENTS AND MAIN RESULTS The primary outcome was incidence of respiratory support escalation within 72 h from sepsis time zero. Respiratory support escalation included high-flow nasal cannula, bilevel positive airway pressure, or intubation. One-hundred and four patients were included with 52 patients in each study group. Patients with PH were more likely to require escalation of respiratory support compared to non-PH patients (32.7% vs. 11.5%; p = 0.009). Fewer patients with PH received 30 mL/kg of crystalloid within 6 h of time zero compared with non-PH patients (3.8% vs. 42.3%; p < 0.001). Vasopressor initiation was more common in patients with PH compared with the non-PH group (40.4% vs. 19.2%; p = 0.018). PH diagnosis was the only independent predictor of respiratory support escalation. CONCLUSIONS During initial sepsis management when compared with patients without PH, patients with PH had increased instances of respiratory support escalation within 72 h of sepsis time zero despite lower fluid resuscitation volumes.
Collapse
|
4
|
Condliffe R, Newton R, Bauchmuller K, Bonnett T, Kerry R, Mannings A, Nair A, Selby K, Skinner PP, Wilson VJ, Kiely DG. Surgery and Anesthesia in Patients with Pulmonary Hypertension. Semin Respir Crit Care Med 2023; 44:797-809. [PMID: 37729924 DOI: 10.1055/s-0043-1772753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
Pulmonary hypertension is characterized by right ventricular impairment and a reduced ability to compensate for hemodynamic insults. Consequently, surgery can be challenging but is increasingly considered in view of available specific therapies and improved longer term survival. Optimal management requires a multidisciplinary patient-centered approach involving surgeons, anesthetists, pulmonary hypertension clinicians, and intensivists. The optimal pathway involves risk:benefit assessment for the proposed operation, optimization of pulmonary hypertension and any comorbidities, the appropriate anesthetic approach for the specific procedure and patient, and careful monitoring and management in the postoperative period. Where patients are carefully selected and meticulously managed, good outcomes can be achieved.
Collapse
Affiliation(s)
- Robin Condliffe
- Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
| | - Ruth Newton
- Department of Anaesthesia, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Kris Bauchmuller
- Department of Critical Care, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Tessa Bonnett
- Department of Obstetrics and Gynaecology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Robert Kerry
- Department of Orthopaedics, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Alexa Mannings
- Department of Anaesthesia, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Amanda Nair
- Department of Anaesthesia, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Karen Selby
- Department of Obstetrics and Gynaecology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Paul P Skinner
- Department of Surgery, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - Victoria J Wilson
- Department of Anaesthesia, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
| | - David G Kiely
- Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
| |
Collapse
|
5
|
Garcia MVF, Souza R, Caruso P. Reply to: "Mortality and prognostic factors in connective tissue disease-associated pulmonary arterial hypertension patients complicated with right heart failure". Int J Rheum Dis 2023; 26:2612-2614. [PMID: 37203868 DOI: 10.1111/1756-185x.14735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 03/08/2023] [Accepted: 05/05/2023] [Indexed: 05/20/2023]
Affiliation(s)
- Marcos Vinicius Fernandes Garcia
- Divisao de Pneumologia, Instituto do Coracao, Hospital das Clínicas HCFMUSP, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Rogerio Souza
- Divisao de Pneumologia, Instituto do Coracao, Hospital das Clínicas HCFMUSP, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Pedro Caruso
- Divisao de Pneumologia, Instituto do Coracao, Hospital das Clínicas HCFMUSP, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
- Intensive Care Unit, AC Camargo Cancer Center, São Paulo, Brazil
| |
Collapse
|
6
|
Pichon J, Roche A, Fauvel C, Boucly A, Mercier O, Ebstein N, Beurnier A, Cortese J, Jevnikar M, Jaïs X, Fartoukh M, Fadel E, Sitbon O, Montani D, Voiriot G, Humbert M, Savale L. Clinical relevance and prognostic value of renal Doppler in acute decompensated precapillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging 2023; 24:1518-1527. [PMID: 37194564 DOI: 10.1093/ehjci/jead104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 04/23/2023] [Accepted: 04/26/2023] [Indexed: 05/18/2023] Open
Abstract
AIMS We aim to evaluate the clinical relevance and the prognostic value of arterial and venous renal Doppler in acute decompensated precapillary pulmonary hypertension (PH). METHODS AND RESULTS The renal resistance index (RRI) and the Doppler-derived renal venous stasis index (RVSI) were monitored at admission and on Day 3 in a prospective cohort of precapillary PH patients managed in intensive care unit for acute right heart failure (RHF). The primary composite endpoint included death, circulatory assistance, urgent transplantation, or rehospitalization for acute RHF within 90 days following inclusion. Ninety-one patients were enrolled (58% female, age 58 ± 16 years). The primary endpoint event occurred in 32 patients (33%). In univariate logistic regression analysis, variables associated with RRI higher than the median value were non-variable parameters (age and history of hypertension), congestion (right atrial pressure and renal pulse pressure), cardiac function [tricuspid annular plane systolic excursion (TAPSE) and left ventricular outflow tract- velocity time integral], systemic pressures and NT-proBNP. Variables associated with RVSI higher than the median value were congestion (high central venous pressure, right atrial pressure, and renal pulse pressure), right cardiac function (TAPSE), severe tricuspid regurgitation, and systemic pressures. Inotropic support was more frequently required in patients with high RRI (P = 0.01) or high RVSI (P = 0.003) at the time of admission. At Day 3, a RRI value <0.9 was associated with a better prognosis after adjusting to the estimated glomerular filtration rate. CONCLUSION Renal Doppler provides additional information to assess the severity of patients admitted to the intensive care unit for acute decompensated precapillary PH.
Collapse
Affiliation(s)
- Jérémie Pichon
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Anne Roche
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Charles Fauvel
- CHU Rouen, Department of Cardiology, F-76000 Rouen, France
- Université Rouen Normandie, Inserm U1096, F-76000 Rouen, France
| | - Athénais Boucly
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Olaf Mercier
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
- Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Hôpital Marie-Lannelongue, 92350 Le Plessis Robinson, France
| | - Nathan Ebstein
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Antoine Beurnier
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Jonathan Cortese
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
- AP-HP, Department of Interventional Neuroradiology, NEURI Brain Vascular Center, Bicêtre Hospital, 94276, Le Kremlin-Bicêtre, France
| | - Mitja Jevnikar
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Xavier Jaïs
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Muriel Fartoukh
- Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, 75020 Paris, France
- Centre de Recherche Saint-Antoine UMRS_938 INSERM, 75012 Paris, France
| | - Elie Fadel
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
- Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Hôpital Marie-Lannelongue, 92350 Le Plessis Robinson, France
| | - Olivier Sitbon
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - David Montani
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Guillaume Voiriot
- Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, 75020 Paris, France
- Centre de Recherche Saint-Antoine UMRS_938 INSERM, 75012 Paris, France
| | - Marc Humbert
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| | - Laurent Savale
- Assistance Publique - Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, France
- Université Paris-Saclay, Faculté de Médecine, 94276 Le Kremlin Bicêtre, France
| |
Collapse
|
7
|
Alshimali H, Coppolino A, Keshk MA, Young JS, Itoh A, Goldberg HJ, Sharma NS, Mallidi HR. Heart recovery and reverse remodeling following lung transplant in pulmonary artery hypertension. THE CARDIOTHORACIC SURGEON 2022. [DOI: 10.1186/s43057-022-00082-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Pulmonary artery hypertension (PAH) is a progressive disease that result in right heart dysfunction. Lung transplantation (LTx) improve survival in end-stage disease. The aim of this study is to assess heart recovery after LTx for patients with primary and secondary pulmonary hypertension.
Methods
We conducted a single center retrospective review for patients with primary and secondary PAH underwent LTx between the period of January 2015 and December 2020. Baseline characteristics and echocardiographic measures were assessed pre-operative and after 1 year follow-up. Survival comparison between primary and secondary PAH was estimated by Kaplan–Meier method.
Results
We identified 43 participants for the study. Among the participants, 11 case had primary PAH. Median age during transplant was 60 years (45.5, 65.5). Left atrium anterio-posterior dimensions, systolic right ventricle pressure tricuspid peal regurgitant velocity and severity of tricuspid regurgitation were found to be significantly improved post-operatively compared to pre-operative echocardiography (p value < 0.05). Overall mortality was not significant between primary and secondary PAH (p value = 0.66).
Conclusions
LTx can reverse heart remodeling and facilitate recovery in primary and secondary PAH. Our data confirm the importance of LTx as a viable option in PAH failing medical treatment.
Collapse
|
8
|
Naranjo M, Mercurio V, Hassan H, Alturaif N, Cuomo A, Attanasio U, Diab N, Sahetya SK, Mukherjee M, Hsu S, Balasubramanian A, Simpson CE, Damico R, Kolb TM, Mathai SC, Hassoun PM. Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. ERJ Open Res 2022; 8:00002-2022. [PMID: 35586454 PMCID: PMC9108967 DOI: 10.1183/23120541.00002-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Accepted: 03/10/2022] [Indexed: 11/05/2022] Open
Abstract
Rationale Pulmonary arterial hypertension (PAH) is a rare disease characterised by limited survival despite remarkable improvements in therapy. The causes, clinical burden and outcomes of patients admitted to the intensive care unit (ICU) remain poorly characterised. The aim of this study was to describe patient characteristics, causes of ICU hospitalisation, and risk factors for ICU and 1-year mortality. Methods Data from patients enrolled in the Johns Hopkins Pulmonary Hypertension Registry were analysed for the period between January 2010 and December 2020. Clinical, functional, haemodynamic and laboratory data were collected. Measurements and main results 102 adult patients with 155 consecutive ICU hospitalisations were included. The leading causes for admission were right heart failure (RHF, 53.3%), infection (17.4%) and arrhythmia (11.0%). ICU mortality was 27.1%. Mortality risk factors included Na <136 mEq·mL-1 (OR: 3.10, 95% CI: 1.41-6.82), elevated pro-B-type natriuretic peptide (proBNP) (OR: 1.75, 95% CI: 1.03-2.98), hyperbilirubinaemia (OR: 1.40, 95% CI: 1.09-1.80), hyperlactaemia (OR: 1.42, 95% CI: 1.05-1.93), and need for vasopressors/inotropes (OR: 5.29, 95% CI: 2.28-12.28), mechanical ventilation (OR: 3.76, 95% CI: 1.63-8.76) and renal replacement therapy (OR: 5.57, 95% CI: 1.25-24.76). Mortality rates at 3, 6 and 12 months were 17.5%, 27.6% and 39.0%, respectively. Connective tissue disease-associated PAH has lower 1-year survival compared to idiopathic PAH (51.4% versus 79.8%, log-rank test p=0.019). Conclusions RHF is the most common cause for ICU admission. In-hospital and 1-year mortality remain exceedingly high despite improved ICU care. Recognising specific risk factors on admission can help identifying patients at risk for poor outcomes.
Collapse
Affiliation(s)
- Mario Naranjo
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
- These authors contributed equally
| | - Valentina Mercurio
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
- Dept of Translational Medical Sciences, Federico II University, Naples, Italy
- These authors contributed equally
| | - Hussein Hassan
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Noura Alturaif
- Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA
| | - Alessandra Cuomo
- Dept of Translational Medical Sciences, Federico II University, Naples, Italy
| | - Umberto Attanasio
- Dept of Translational Medical Sciences, Federico II University, Naples, Italy
| | - Nermin Diab
- Dept of Medicine, Division of Respirology, University of Toronto, Toronto, ON, Canada
| | - Sarina K. Sahetya
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Monica Mukherjee
- Division of Cardiology, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Steven Hsu
- Division of Cardiology, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Aparna Balasubramanian
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Catherine E. Simpson
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Rachel Damico
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Todd M. Kolb
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Stephen C. Mathai
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | - Paul M. Hassoun
- Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
9
|
Kouchit Y, Morand L, Martis N. Mortality and its risk factors in critically ill patients with connective tissue diseases: A meta-analysis. Eur J Intern Med 2022; 98:83-92. [PMID: 35151541 DOI: 10.1016/j.ejim.2022.02.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Revised: 01/16/2022] [Accepted: 02/01/2022] [Indexed: 12/22/2022]
Abstract
BACKGROUND Systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM) and rheumatoid arthritis (RA) are connective tissue diseases (CTD) whose complications can lead to management in the intensive care unit (ICU). OBJECTIVES To estimate by meta-analysis ICU mortality rates for CTD. METHODS A systematic literature review was performed to identify articles studying critically ill CTD patients. A random-effects model was chosen for analysis. Pooled proportion mortality was calculated using aggregated-data meta-analysis with a random-effects model and assessment of heterogeneity with the I2 statistic. Risk of bias was assessed using the quality assessment tool. RESULTS Of the 5694 individual publications, a sample of 31 independent cohorts was used for the meta-analysis totalling 5007 patients. The main cause for admission was sepsis (43%) followed by "flare-ups" (40%). The overall pooled proportion of mortality of CTD patients across all 31 studies was 33% (95%CI: 28-38%). In the IIM subgroup and that of SSc, mortality was 70% (95%CI: 46-86%) and 40% (95%CI: 25-47%), respectively. In the SLE subgroup, mortality was similar to the overall pooled mortality of 35% (95%CI: 29-42%). Subgroup mortality for RA and pSS patients was respectively 20% (95%CI: 11-33%) and 17% (95%CI: 6-41%); lower than the overall pooled mortality. Heterogeneity in each subgroup remained high. CONCLUSION The overall pooled proportion of mortality of ICU patients with CTD was 33% (95%CI: 28-38%), with a high heterogeneity (I2= 89%). In the subgroup analysis, mortality was higher for patients with IIM and SSc.
Collapse
Affiliation(s)
- Yanis Kouchit
- Department of Internal Medicine and Clinical Immunology, University Hospital of Nice, Archet Hospital, 151 route de Saint-Antoine de Ginestière, 06200, Nice, France; Côte d'Azur University, Medical School of Nice, 28 avenue de Valombrose, 06107, Nice, France
| | - Lucas Morand
- Côte d'Azur University, Medical School of Nice, 28 avenue de Valombrose, 06107, Nice, France; Department of Medical Intensive Care, University Hospital of Nice, Archet Hospital, 151 route de Saint-Antoine de Ginestière, 06200, Nice, France
| | - Nihal Martis
- Department of Internal Medicine and Clinical Immunology, University Hospital of Nice, Archet Hospital, 151 route de Saint-Antoine de Ginestière, 06200, Nice, France; Côte d'Azur University, Medical School of Nice, 28 avenue de Valombrose, 06107, Nice, France.
| |
Collapse
|
10
|
Condliffe R, Bauchmuller K, Southern J, Kiely DG, Mills GH. Comment on “External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension”. ERJ Open Res 2022; 8:00066-2022. [PMID: 35265702 PMCID: PMC8899494 DOI: 10.1183/23120541.00066-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 02/04/2022] [Indexed: 11/17/2022] Open
Abstract
We were very interested to read the correspondence by M.V.F. Garcia and colleagues [1]. They have assessed our previously proposed predictive score for outcomes in medically decompensated pulmonary hypertension (PH) patients: the OPALS score (oxygen (oxygen saturation measured by pulse oximetry/inspiratory oxygen fraction ratio ⩽185), platelets ⩽196×109 L−1, age ⩾37.5 years, lactate ⩾2.45 mmol·L−1 and sodium ⩽130.5 mmol·L−1) in 74 PH patients. Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78) [2]. Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R2=0.97). The OPALS score therefore appears to be a promising PH-specific tool for predicting outcomes in medically decompensated patients. Further work is, however, needed to compare its accuracy and utility compared with other intensive care unit (ICU) scoring systems and PH risk-stratification tools, and to assess its responsiveness to changing clinical severity during patients’ ICU admission. The OPALS score appears to be a promising PH-specific tool for predicting outcomes in medically decompensated patientshttps://bit.ly/3rTxzbr
Collapse
|
11
|
Garcia MVF, Souza R, Caruso P. External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension. ERJ Open Res 2022; 8:00006-2022. [PMID: 35265704 PMCID: PMC8899496 DOI: 10.1183/23120541.00006-2022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Accepted: 01/21/2022] [Indexed: 11/05/2022] Open
|
12
|
Barnett CF, O'Brien C, De Marco T. Critical care management of the patient with pulmonary hypertension. EUROPEAN HEART JOURNAL. ACUTE CARDIOVASCULAR CARE 2022; 11:77-83. [PMID: 34966914 DOI: 10.1093/ehjacc/zuab113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 11/10/2021] [Indexed: 06/14/2023]
Abstract
Pulmonary hypertension (PH) is a common diagnosis in patients admitted to the cardiac intensive care unit with a wide range of underlying causes. A detailed evaluation to identify all factors contributing to the elevated pulmonary artery pressure and provide an assessment of right ventricular haemodynamics and function is needed to guide treatment and identify patients at highest risk for poor outcomes. While in many patients management of underlying and triggering medical problems with careful monitoring is appropriate, a subset of patients may benefit from specialized treatments targeting the pulmonary circulation and support of the right ventricle. In such cases, collaboration with or transfer to a centre with special expertise in the management of PH may be warranted.
Collapse
Affiliation(s)
- Christopher F Barnett
- Department of Medicine, Cardiology Division, University of California, San Francisco, 505 Parnassus Avenue, Room S1134A, San Francisco, CA 94143, USA
| | - Connor O'Brien
- Department of Medicine, Cardiology Division, University of California, San Francisco, 505 Parnassus Avenue, Room S1134A, San Francisco, CA 94143, USA
| | - Teresa De Marco
- Department of Medicine, Cardiology Division, University of California, San Francisco, 505 Parnassus Avenue, Room S1134A, San Francisco, CA 94143, USA
| |
Collapse
|
13
|
Wardle M, Nair A, Saunders S, Armstrong I, Charalampopoulos A, Elliot C, Hameed A, Hamilton N, Harrington J, Keen C, Lewis R, Sabroe I, Thompson AAR, Kerry RM, Condliffe R, Kiely DG. Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension. Pulm Circ 2022; 12:e12019. [PMID: 35506074 PMCID: PMC9053006 DOI: 10.1002/pul2.12019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 10/14/2021] [Accepted: 10/30/2021] [Indexed: 11/08/2022] Open
Abstract
Patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PH) are at increased risk when undergoing anesthesia and major surgery. Data on outcomes for elective orthopedic surgery in patients with PH are limited. A patient pathway was established to provide access to elective lower limb arthroplasty. This included assessment of orthopedic needs, fitness for anesthesia, preoperative optimization, and intra- and postoperative management. Patient data were retrospectively retrieved using patient's hospital records. Between 2012 and 2020, 29 operations (21 total hip replacements [THRs], 7 total knee replacements [TKRs], 1 total hip revision) were performed in 25 patients (mean age: 67 years). Perioperatively, 72% were treated with low-dose intravenous prostanoid. All had arterial lines, and central access and perioperative lithium dilution cardiac output monitoring was used in 86% of cases. Four patients underwent GA, 21 spinal anesthesia, and 4 CSE anesthesia. Supplemental nerve blocks were performed in all patients undergoing general, and 12 of 21 undergoing spinal anesthesia. All were managed in high dependency postoperatively. Hospital length of stay and complication rates were higher than reported in non-PH patients. Perioperative complications included hypotension requiring vasopressors (n = 10), blood transfusion (n = 7), nonorthopedic infection (n = 4), and decompensated right heart failure (n = 1). There was no associated mortality. All implants were functioning well at 6 weeks and subsequent follow-up. EmPHasis-10 quality of score decreased by 5.5 (±2.1) (p = 0.04). A dedicated multiprofessional pathway can be used to safely select and manage patients with PH through elective lower limb arthroplasty.
Collapse
Affiliation(s)
- Mikaela Wardle
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK.,Department of Anaesthetics Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Amanda Nair
- Department of Anaesthetics Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Sarah Saunders
- Department of Anaesthetics Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Iain Armstrong
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | | | - Charlie Elliot
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Abdul Hameed
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK.,Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK
| | - Neil Hamilton
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - John Harrington
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Carol Keen
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Robert Lewis
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK.,Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK
| | - Ian Sabroe
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - A A Roger Thompson
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK.,Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK
| | - Robert M Kerry
- Department of Orthopaedic Surgery Sheffield Teaching Hospitals NHS Trust Sheffield UK
| | - Robin Condliffe
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK.,Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK
| | - David G Kiely
- Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Trust Sheffield UK.,Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK
| |
Collapse
|
14
|
Critical Care Management of Decompensated Right Heart Failure in Pulmonary Arterial Hypertension Patients - An Ongoing Approach. J Crit Care Med (Targu Mures) 2021; 7:170-183. [PMID: 34722920 PMCID: PMC8519386 DOI: 10.2478/jccm-2021-0020] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 06/21/2021] [Indexed: 11/20/2022] Open
Abstract
Despite substantial advancements in diagnosis and specific medical therapy in pulmonary arterial hypertension patients’ management, this condition continues to represent a major cause of mortality worldwide. In pulmonary arterial hypertension, the continuous increase of pulmonary vascular resistance and rapid development of right heart failure determine a poor prognosis. Against targeted therapy, patients inexorable deteriorate over time. Pulmonary arterial hypertension patients with acute right heart failure who need intensive care unit admission present a complexity of the disease pathophysiology. Intensive care management challenges are multifaceted. Awareness of algorithms of right-sided heart failure monitoring in intensive care units, targeted pulmonary hypertension therapies, and recognition of precipitating factors, hemodynamic instability and progressive multisystem organ failure requires a multidisciplinary pulmonary hypertension team. This paper summarizes the management strategies of acute right-sided heart failure in pulmonary arterial hypertension adult cases based on recently available data.
Collapse
|